NEW YORK (GenomeWeb) – Investment bank Evercore ISI said today that it has initiated coverage of Abbott with an Outperform rating and target price of $64 per share, Hologic with an Outperform rating and a target price of $50 per share, and Becton Dickinson with an Outperform rating and a target price of $245 per share.

Evercore ISI analyst Vijay Kumar said that initiating coverage of the three diagnostic companies coincides with re-initiating coverage of the medical technology (MedTech) sector.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.